Smithkline Beecham Corporation

Brian David Judkins

Andrew Michael Kenneth Pennell

Hazel Joan Dyke

David E Bays

Colin David Eldred

Richard Peter Charles Cousins

Martin Pass

Philip Charles Box

A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor. The adenosine derivative has a general formula (I) as follows:

Adenosine derivatives and methods of administration

A compound of formula (I) which is an agonist at the adenosine Al receptor, wherein Y, Z, and W represent heteroatoms, and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof for use in therapy.

Adenosine derivatives

A compound of formula (I) wherein R represents C alkyl, halogen or hydrogen; R represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists of the Adenosine A1 receptor.

Adenosine analogues and related method of treatment

Growing community of inventors

Stevenage, United Kingdom

Brian David Judkins